Practice Point® CME Podcasts: Expert Discussions in Hematology™

CAR T-cell therapies have transformed the management of several previously incurable, treatment-refractory hematologic malignancies, including Multiple Myeloma (MM). With two CAR T-cell products now approved, and additional under investigation, the therapeutic landscape continues to evolve rapidly.In this educational podcast, Dr. Joseph Mikhael highlights key advances in CAR T-cell therapy for MM. He reviews the most impactful data published or presented in 2025 and offers expert insight into how these emerging findings may shape current and future treatment strategies.Launch/Release Date: December 17, 2025 Activity Expiration Date: November 30, 2026FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACP, FASCOProfessor, Clinical Genomics and Therapeutics Translational Genomics Research Institute (TGen), City of Hope Cancer Center Chief Medical Officer International Myeloma FoundationThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

A number of clinical trials are underway to reduce and prevent bleeding episodes among patients with hemophilia and to improve their overall quality of life by improving joint health and addressing patient needs/concerns. These include both replacement and novel non-replacement therapies. This activity is designed to update healthcare professionals with the latest cutting-edge evidence in hemophilia treatment that was presented during the annual hematology meeting in Orlando, FL.The Clinical Clips format will equip clinicians with the knowledge and confidence to integrate new evidence into personalized approaches, optimize patient outcomes, and improve the overall quality of care in hemophilia A and B.Launch/Release Date: December 12, 2025 Activity Expiration Date: November 30, 2026FACULTYAngela Weyand, MDAssociate Professor, Pediatrics University of Michigan Medical School Pediatric Medical Director University of Michigan HTC Co-Director, Hematology and Pediatric and Adolescent Gynecology Program Ann Arbor, MichiganThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Breakthroughs in hematologic cancers continue to emerge. Staying aligned with the newest insights from leading medical conferences is essential for healthcare providers committed to delivering cutting-edge care.Through impactful presentations, posters and abstracts, Dr. Raajit Rampal provides expert commentary on the latest advances in Leukemia, Myelodysplastic Syndromes (MDS) and Myelofibrosis (MF) presented at the annual hematology meeting in Orlando, FL.Launch/Release Date: December 10, 2025Activity Expiration Date: November 30, 2026FACULTYRaajit Rampal, MD, PhDDirector, Myeloproliferative Neoplasms ProgramDirector, Center for Hematologic MalignanciesMemorial Sloan Kettering Cancer CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this podcast, Dr. Cindy Neunert, provides expert insights into emerging data on ITP pathophysiology, diagnosis, and treatment, equipping healthcare providers with the knowledge to translate new research into clinical practice and improve pediatric patient care.Launch Date: July 7, 2025Release Date: July 7, 2025Expiration Date: June 30, 2026FACULTYCindy Neunert, MDDivision of Pediatric HematologyOncology, and Stem Cell TransplantationColumbia University Irving Medical CenterNew York, New YorkThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.Launch Date: February 4, 2025Release Date: February 4, 2025Expiration Date: January 31, 2026FACULTYJonathan C. Roberts, MDAssociate Medical DirectorAssociate Research DirectorBleeding and Clotting Disorders InstituteAssociate Professor of Pediatrics and MedicineUniversity of Illinois College of Medicine at PeoriaMindy Simpson, MDMedical DirectorRush Hemophilia and Thrombophilia CenterAssistant Professor of Pediatrics in Pediatric Hematology/OncologyRush University Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.Launch Date: February 4, 2025Release Date: February 4, 2025Expiration Date: January 31, 2026FACULTYJonathan C. Roberts, MDAssociate Medical DirectorAssociate Research DirectorBleeding and Clotting Disorders InstituteAssociate Professor of Pediatrics and MedicineUniversity of Illinois College of Medicine at PeoriaMindy Simpson, MDMedical DirectorRush Hemophilia and Thrombophilia CenterAssistant Professor of Pediatrics in Pediatric Hematology/OncologyRush University Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.Launch Date: February 4, 2025Release Date: February 4, 2025Expiration Date: January 31, 2026FACULTYJonathan C. Roberts, MDAssociate Medical DirectorAssociate Research DirectorBleeding and Clotting Disorders InstituteAssociate Professor of Pediatrics and MedicineUniversity of Illinois College of Medicine at PeoriaMindy Simpson, MDMedical DirectorRush Hemophilia and Thrombophilia CenterAssistant Professor of Pediatrics in Pediatric Hematology/OncologyRush University Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

There has been unprecedented research progress in the treatment of hemophilia heralded by the development of non-replacement therapies, emerging factor mimetics, and novel gene therapy agents. In this podcast series, Dr. Jonathan C. Roberts and Dr. Mindy Simpson inform and guide on safely integrating recently approved agents into the treatment continuum while ensuring alignment with critical new breakthroughs and enabling patient-focused care pathways.Launch Date: February 4, 2025Release Date: February 4, 2025Expiration Date: January 31, 2026FACULTYJonathan C. Roberts, MDAssociate Medical DirectorAssociate Research DirectorBleeding and Clotting Disorders InstituteAssociate Professor of Pediatrics and MedicineUniversity of Illinois College of Medicine at PeoriaMindy Simpson, MDMedical DirectorRush Hemophilia and Thrombophilia CenterAssistant Professor of Pediatrics in Pediatric Hematology/OncologyRush University Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information here prior to listening to this episode.

Conversations in IFN-y explores the latest advancements in understanding and managing secondary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS), with updates from ASH 2024. Featuring discussions by leading experts, the educational activity covers breakthroughs in diagnostic technologies. Topics covered include AI-based histology models and PET/CT imaging, therapeutic innovations such as emapalumab and reduced-intensity conditioning for HSCT. The implications of these findings for improving outcomes in diverse patient populations, including malignancy- and pregnancy-associated HLH will also be discussed.Launch Date: January 9, 2025Release Date: January 9, 2025Expiration Date: December 31, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children's Hospital Medical CenterAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children’s Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

What’s New Doc?: CAR T-cells in Multiple Myeloma, highlights key studies and publications from 2024 on the use of these agents in earlier lines of treatment. Dr. Mikhael details how approved and emerging CAR T cell agents in multiple myeloma will impact the treatment landscape and how to better integrate these agents to enable improved outcomes among patients.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this Conversations in IFN-y podcast episode, emerging data from the 2024 ACR meeting is discussed, highlighting advancements in understanding genetic drivers, cytokine dynamics, and biomarkers like IL-18 and CXCL9 for improved diagnosis and monitoring. Expert insights explore new findings on liver and lung pathology in MAS, as well as updates on therapeutic innovations, including JAK inhibitors and emapalumab, and their roles in enhancing patient outcomes. Practical strategies are provided for integrating the latest research and cutting-edge diagnostics into clinical practice.Launch Date: December 19, 2024Release Date: December 19, 2024Expiration Date: November 30, 2025FACULTYPui Lee, MDAssistant Professor of PediatricsBoston Children's HospitalAlexei Grom, MDProfessor of PediatricsResearch DirectorDivision of RheumatologyCincinnati Children’s Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In Highlights and Hindsight in CLL, Dr. Matthew Davids will describe the most significant ongoing studies and publications in CLL from 2024 and will detail their impact on the treatment continuum. This activity will enable participants to stay updated on the most relevant breakthroughs and improve outcomes among patients.Launch Date: December 18, 2024Release Date: December 18, 2024Expiration Date: November 30, 2025FACULTYMatthew Davids, MD, MMScDirector of Clinical Research, Division of LymphomaDana-Farber Cancer InstituteThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.Launch Date: December 16, 2024Release Date: December 16, 2024Expiration Date: November 30, 2025FACULTYNaval Daver, MDDirector, Leukemia Research Alliance Program,Professor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link prior to listening to this podcast.

Clinical Clips in Hemophilia: Cutting-Edge Advances Presented at ASH 2024, will focus on the most exciting abstracts in hemophilia A and B that would be impactful for improved patient care. Dr. Guy Young will discuss the utility of key new evidence on replacement and non-replacement therapy to overcome current limitations and enable improved outcomes among patients.Launch Date: December 12, 2024Release Date: December 12, 2024Expiration Date: November 30, 2025FACULTYGuy Young, MDProfessor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips-in-hemophilia-cutting-edge-advances-presented-at-ash-2024-1

This third podcast episode in the series explores advanced understanding of primary hemophagocytic lymphohistiocytosis (HLH), focusing on its genetic basis, diagnostic innovations, and treatment strategies. The discussion highlights the pathophysiology of HLH as an interferon gamma (IFN-γ) driven disease, emphasizing the role of novel diagnostic tools such as flow cytometry and genetic panels. The panel also examines emerging therapies, including JAK inhibitors and IFN-γ monoclonal antibody (emapalumab), in improving outcomes for both primary and secondary HLH. Practical insights into balancing immunosuppression with efficacy offer guidance for optimizing patient care.Launch Date: December 2, 2024Release Date: December 2, 2024Expiration Date: November 30, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children’s Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.Launch Date: November 25, 2024Release Date: November 25 2024Expiration Date: October 31, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children’s Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Patients with interferon gamma (IFN-γ)-driven diseases such as hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) face significant diagnostic and therapeutic challenges, with delays in diagnosis and limited effective treatments often resulting in poor outcomes. Despite advances in understanding the role of IFN-γ in these conditions, there remains an unmet need for more precise diagnostic tools and faster, targeted therapies to manage the hyperinflammatory states that characterize these diseases.Launch Date: November 18, 2024Release Date: November 18, 2024Expiration Date: October 31, 2025FACULTYScott Canna, MDAssistant Professor of PediatricsChildrens Hospital of PhiladelphiaPui Lee, MDAssistant Professor of PediatricsBoston Childrens HospitalAshish Kumar, MD, PhDProfessor of PediatricsCincinnati Children’s Hospital Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/conversations-in-ifn-y-driven-diseases-decoding-the-gamma-signal-1

Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.Launch Date: October 1, 2024Release Date: October 1, 2024Expiration Date: September 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityCaitlin Costello, MDClinical Professor of MedicineDirector, Multiple Myeloma ProgramDivision of Blood and Marrow TransplantationMoores Cancer CenterUC San DiegoThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/relapsedrefractory-multiple-myeloma-podcast-series-clinical-viewpoints-to-individualize-bispecific-antibody-therapy

Bispecific antibodies represent a much-needed option for diverse patients with relapsed/refractory multiple myeloma (RRMM). This podcast activity will highlight key clinical trial evidence leading to approval of bispecific antibodies and will provide guidance on safely incorporating these agents into RRMM treatment paradigms. Clinical case scenarios will also be discussed to optimize and sequence bispecific antibodies to enable improved outcomes among distinct patient subsets.Launch Date: October 1, 2024Release Date: October 1, 2024Expiration Date: September 30, 2025FACULTYJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversityCaitlin Costello, MDClinical Professor of MedicineDirector, Multiple Myeloma ProgramDivision of Blood and Marrow TransplantationMoores Cancer CenterUC San DiegoThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/relapsedrefractory-multiple-myeloma-podcast-series-clinical-viewpoints-to-individualize-bispecific-antibody-therapy

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

In this podcast series, Dr. Orlowski, Dr. Raje, and Dr. Voorhees inform and guide participants on latest developments from clinical trials on quadruplet and triplet regimens, based on updates from the European Hematology Association (EHA) 2024 meeting. Using clinical case scenarios, they’ll clarify clinical endpoints and outcomes to enable safe and effective frontline regimen choices among diverse patients with newly diagnosed multiple myeloma (NDMM) who have distinct needs. Listen to the available episodes as experts lay the foundation for optimal first-line, maintenance, transplantation, and subsequent therapy choice based on the risk profile of patients, to ultimately improve outcomes in multiple myeloma (MM).Launch Date: July 19, 2024Release Date: June 26, 2024Expiration Date: June 30, 2025FACULTYRobert Orlowski, MD, PhDProfessor of MedicineDirector, Section of MyelomaThe University of Texas, MD Anderson Cancer CenterNoopur Raje, MDDirector, Center for Multiple MyelomaMassachusetts General HospitalPeter Voorhees, MDChief, Plasma Cell Disorders DivisionAtrium Health / Levine Cancer InstituteClinical Professor of MedicineWake Forest University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/integrating-quadruplet-regimens-in-newly-diagnosed-multiple-myeloma-patient-focused-strategies-to-improve-outcomes-43

This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of MF presented at the 2024 European Hematology Association (EHA 2024) Hybrid Congress, June 13-16, Madrid, Spain.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector of the Center of Excellence for Blood Cancers and Myeloid DisordersNew York, New YorkThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcast-from-eha-2024-advancements-in-myelofibrosis-from-pathophysiology-to-personalized-treatment-strategies

This podcast will ensure that HCPs who treat / manage patients with NDMM are up-to-date on key data presented at the 2024 European Hematology Association Annual Congress (EHA 2024), June 13-16, 2024 in Madrid, Spain and will aid learners in safely applying recent evidence into practice.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025Faculty BioPeter Voorhees, MDClinical Professor, Hematology and OncologyWake Forest University School of MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/podcasts-in-advanced-newly-diagnosed-multiple-myeloma-updates-from-eha-2024

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disease characterized by a low platelet count, purpura, and hemorrhagic episodes caused by antiplatelet autoantibodies. Diagnosis is typically made by excluding the known causes of thrombocytopenia. Recent advancements in pediatric ITP treatment show promise for personalized medicine and better outcomes. This podcast will provide expert interpretation of new and emerging data on the pathophysiology, diagnosis and treatment of pediatric ITP presented at the EHA 2024 Hybrid Congress, June 13-16, Madrid, Spain.Launch Date: June 17, 2024Release Date: June 17, 2024Expiration Date: May 31, 2025FACULTYCindy Neunert, MDAssociate Professor of PediatricsColumbia University Irving Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast. https://www.practicepointcme.com/CMEHome/podcasts-in-pediatric-itp-advancements-in-pediatric-itp-management-insights-from-eha-2024

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC/ACPE podcasts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.Launch Date: May 2, 2024Release Date: May 2, 2024Expiration Date: April 30, 2025FACULTY BIOJesús G. Berdeja, MDDirector of Multiple Myeloma ResearchThe Greco-Hainsworth Tennessee Oncology Centers for ResearchJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversitySaad Usmani, MDChief, Myeloma ServiceMemorial Sloan Kettering Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-relapsedrefractory-multiple-myeloma-strategies-to-effectively-introduce-optimize-and-sequence-bispecific-antibody-therapy-8

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC/ACPE podcasts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.Launch Date: May 2, 2024Release Date: May 2, 2024Expiration Date: April 30, 2025FACULTY BIOJesús G. Berdeja, MDDirector of Multiple Myeloma ResearchThe Greco-Hainsworth Tennessee Oncology Centers for ResearchJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversitySaad Usmani, MDChief, Myeloma ServiceMemorial Sloan Kettering Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-relapsedrefractory-multiple-myeloma-strategies-to-effectively-introduce-optimize-and-sequence-bispecific-antibody-therapy-8

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). These certified AMA/ABS/ANCC/ACPE podcasts summarize the rationale/mechanism of action and clinical evidence on approved and emerging bispecific antibody therapy in RRMM and aid participants in using these agents safely by using clinical vignettes. The activity also provides guidance on early recognition of key adverse events and strategies to manage them, to ultimately improve outcomes for patients with RRMM.Launch Date: May 2, 2024Release Date: May 2, 2024Expiration Date: April 30, 2025FACULTY BIOJesús G. Berdeja, MDDirector of Multiple Myeloma ResearchThe Greco-Hainsworth Tennessee Oncology Centers for ResearchJoseph Mikhael, MD, MEd, FRCPC, FACPProfessor, Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer CenterChief Medical Officer, International Myeloma FoundationConsultant Hematologist and Director, Myeloma Research, Phase 1 Program, HonorHealth Research InstituteAdjunct Professor, College of Health Solutions, Arizona State UniversitySaad Usmani, MDChief, Myeloma ServiceMemorial Sloan Kettering Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-relapsedrefractory-multiple-myeloma-strategies-to-effectively-introduce-optimize-and-sequence-bispecific-antibody-therapy-8

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17

This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17

This Conversations in MF podcast will discuss the most clinically relevant data and emerging strategies into practice to improve outcomes for patients with MF presented from the 2023 international meetings of the American Society of Clinical Oncology (ASCO), European Hematology Association (EHA) and Society of Hematologic Oncology (SOHO).Launch Date: January 29, 2024Release Date: January 29, 2024Expiration Date: December 30, 2024FACULTY BIOSPrithviraj Bose, MDProfessor, Department of Leukemia, Division of Cancer MedicineUniversity of TexasMD Anderson Cancer CenterJohn Mascarenhas, MDProfessor of MedicineIcahn School of Medicine at Mount SinaiDirector, Center of Excellence in Blood Cancers and Myeloid DisordersRuben Mesa, MDExecutive DirectorAtrium Health Wake Forest Baptist Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conference-briefs-highlighting-myelofibrosis-clinical-data-from-key-conferences-17

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). In these dynamic and interactive podcast sessions, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes. Two case presentations will be discussed to help clinicians select the most appropriate treatment as well as incorporate patient reported outcomes and shared decision making into their routine clinical practice.Launch Date: December 28, 2023Release Date: December 28, 2023Expiration Date: November 30, 2024FACULTY BIOSJames Bussel, MDProfessor EmeritusPediatric Hematology-OncologyWeill Cornell Medicine New YorkNew York, NYCindy Neunert, MDDivision of Pediatric HematologyOncology, and Stem Cell TransplantationColumbia University Irving Medical CenterNew York, NYThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-itp-how-do-emerging-treatment-strategies-have-the-potential-to-transform-patient-outcomes-39

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). In these dynamic and interactive podcast sessions, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes. Two case presentations will be discussed to help clinicians select the most appropriate treatment as well as incorporate patient reported outcomes and shared decision making into their routine clinical practice.Launch Date: December 28, 2023Release Date: December 28, 2023Expiration Date: November 30, 2024FACULTY BIOSJames Bussel, MDProfessor EmeritusPediatric Hematology-OncologyWeill Cornell Medicine New YorkNew York, NYCindy Neunert, MDDivision of Pediatric HematologyOncology, and Stem Cell TransplantationColumbia University Irving Medical CenterNew York, NYThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-itp-how-do-emerging-treatment-strategies-have-the-potential-to-transform-patient-outcomes-39

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). In these dynamic and interactive podcast sessions, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes. Two case presentations will be discussed to help clinicians select the most appropriate treatment as well as incorporate patient reported outcomes and shared decision making into their routine clinical practice.Launch Date: December 28, 2023Release Date: December 28, 2023Expiration Date: November 30, 2024FACULTY BIOSJames Bussel, MDProfessor EmeritusPediatric Hematology-OncologyWeill Cornell Medicine New YorkNew York, NYCindy Neunert, MDDivision of Pediatric HematologyOncology, and Stem Cell TransplantationColumbia University Irving Medical CenterNew York, NYThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/expert-insights-on-itp-how-do-emerging-treatment-strategies-have-the-potential-to-transform-patient-outcomes-39

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). In these dynamic and interactive podcast sessions, Dr. James Bussel and Dr. Cindy Neunert discuss emerging evidence for management strategies for ITP, including utilization of patient reported outcomes and shared decision making to improve outcomes. Two case presentations will be discussed to help clinicians select the most appropriate treatment as well as incorporate patient reported outcomes and shared decision making into their routine clinical practice.Launch Date: December 28, 2023 Release Date: December 28, 2023 Expiration Date: November 30, 2024FACULTY BIOS James Bussel, MD Professor Emeritus Pediatric Hematology-Oncology Weill Cornell Medicine New York New York, NYCindy Neunert, MD Division of Pediatric Hematology Oncology, and Stem Cell Transplantation Columbia University Irving Medical Center New York, NYThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/expert-insights-on-itp-how-do-emerging-treatment-strategies-have-the-potential-to-transform-patient-outcomes-39

Novel therapies targeting the immune system and their combinations are gaining ground in AML. This podcast series, led by expert faculty, will clarify the potential and utility of innovative therapies that harness the immune system and will provide guidance on their applicability into clinical practice, especially for elderly/unfit patients with AML. Launch Date: December 27, 2023Release Date: December 27, 2023Expiration Date: November 30, 2024FACULTY BIOSTapan Kadia, MDMD Anderson Cancer InstituteUniversity of TexasDaniel Pollyea, MDProfessor of MedicineUniversity of Colorado School of MedicineDepartment of HematologyEunice Wang, MDProfessor of OncologyChief, Leukemia/Benign Hematology ServiceDepartment of MedicineMedical Director, Chemo/Infusion ClinicsRosewell Park Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-acute-myeloid-leukemia-novel-therapies-targeting-the-immune-system-for-elderlyunfit-patients-1

Novel therapies targeting the immune system and their combinations are gaining ground in AML. This podcast series, led by expert faculty, will clarify the potential and utility of innovative therapies that harness the immune system and will provide guidance on their applicability into clinical practice, especially for elderly/unfit patients with AML. Launch Date: December 27, 2023Release Date: December 27, 2023Expiration Date: November 30, 2024FACULTY BIOSTapan Kadia, MDMD Anderson Cancer InstituteUniversity of TexasDaniel Pollyea, MDProfessor of MedicineUniversity of Colorado School of MedicineDepartment of HematologyEunice Wang, MDProfessor of OncologyChief, Leukemia/Benign Hematology ServiceDepartment of MedicineMedical Director, Chemo/Infusion ClinicsRosewell Park Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-acute-myeloid-leukemia-novel-therapies-targeting-the-immune-system-for-elderlyunfit-patients-1

Novel therapies targeting the immune system and their combinations are gaining ground in AML. This podcast series, led by expert faculty, will clarify the potential and utility of innovative therapies that harness the immune system and will provide guidance on their applicability into clinical practice, especially for elderly/unfit patients with AML. Launch Date: December 27, 2023Release Date: December 27, 2023Expiration Date: November 30, 2024FACULTY BIOSTapan Kadia, MDMD Anderson Cancer InstituteUniversity of TexasDaniel Pollyea, MDProfessor of MedicineUniversity of Colorado School of MedicineDepartment of HematologyEunice Wang, MDProfessor of OncologyChief, Leukemia/Benign Hematology ServiceDepartment of MedicineMedical Director, Chemo/Infusion ClinicsRosewell Park Comprehensive Cancer CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-acute-myeloid-leukemia-novel-therapies-targeting-the-immune-system-for-elderlyunfit-patients-1

This is an accredited continuing education series of one (1) podcast as a downloadable audio file (MP3). This certified AMA/ABS/ANCC podcast will spotlight latest advances in the treatment of ITP featuring a leading expert reporting from the 2023 ASH Conference.Launch Date: December 19, 2023Release Date: December 19, 2023Expiration Date: November 30, 2024FACULTY BIOHanny Al-Samkari, MDThe Peggy S. Blitz Endowed Chair in Hematology/OncologyAssociate Professor of Medicine,Harvard Medical SchoolCo-Director, Hereditary Hemorrhagic Telangiectasia Center of ExcellenceMassachusetts General Hospital, Boston, MAThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/clinical-clips174-spotlighting-hot-topics-in-itp

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023Expiration Date: October 31, 2024FACULTY BIOSAngela Weyand, MDAssociate Professor of MedicineUniversity of Michigan Medical SchoolGuy Young, MDProfessor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023Expiration Date: October 31, 2024FACULTY BIOSAngela Weyand, MDAssociate Professor of MedicineUniversity of Michigan Medical SchoolGuy Young, MDProfessor of PediatricsUniversity of Southern California Keck School of MedicineDirector, Hemostasis and Thrombosis CenterChildren’s Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023 Expiration Date: October 31, 2024FACULTY BIOS Angela Weyand, MD Associate Professor of Medicine University of Michigan Medical SchoolGuy Young, MD Professor of Pediatrics University of Southern California Keck School of Medicine Director, Hemostasis and Thrombosis Center Children’s Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44

This is an accredited continuing education series of four (4) podcasts as downloadable audio files (MP3). During this podcast series, Guy Young, MD, and Angela Weyand, MD, will inform and guide on keeping up with recent progress and safely integrating it into clinical treatment paradigms of severe hemophilia A. Topics covered include recent practice-changing updates in replacement and non-replacement therapies in hemophilia A, case presentations to aid in selecting the most appropriate treatment for diverse patients with severe hemophilia A, novel non-replacement therapy and gene therapy as well as case scenarios to examine the utility of gene therapy.Launch Date: November 21, 2023Release Date: November 21, 2023 Expiration Date: October 31, 2024FACULTY BIOS Angela Weyand, MD Associate Professor of Medicine University of Michigan Medical SchoolGuy Young, MD Professor of Pediatrics University of Southern California Keck School of Medicine Director, Hemostasis and Thrombosis Center Children’s Hospital Los AngelesThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode. https://www.practicepointcme.com/CMEHome/practice-changing-updates-the-evolving-treatment-landscape-in-hemophilia-a-44